Source: Annual Congress 2008 - Therapy in thoracic oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
C. He, M. Liu, J. Xu (Guangzhou, China). Detection of epidermal growth factor receptor mutation in plasma as predictor of gefitinib response in non small cell lung cancer. Eur Respir J 2008; 32: Suppl. 52, 1551

Member's Comments

No comment yet.

Related content which might interest you: The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer Source: Eur Respir J 2011; 37: 183-193 Year: 2011 A blood-based test for epidermal growth factor receptor mutations in patients with non-small cell lung cancer Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008 Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up Source: Eur Respir J 2009; 33: 436-440 Year: 2009 Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 Characteristics of common and uncommon epidermal growth factor receptros gene mutations in patients with non small cell lung cancer Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017 Prognostic significance of epidermal growth factor receptor expression in nonsmall cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002 Epidermal growth factor receptor mutation status in advanced non-small cell lung cancer: A single institution experience Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Inhibition of insulin-like growth factor type I (IGF-I) gene in A549 human lung cancer cell line enhances cell apoptosis and causes phenotype changes relevant to increased tumor susceptibility to immune system Source: Eur Respir J 2007; 30: Suppl. 51, 715s Year: 2007 Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer Source: Eur Respir J 2005; 25: 329-335 Year: 2005 Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker Source: International Congress 2019 – Biology of lung cancer Year: 2019 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 366-372 Year: 2012 Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) as a prognostic factor of survival in patients with lung adenocarcinoma Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008 Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer. Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Potential role of short hairpin RNA targeting epidermal growth factor receptor in growth and sensitivity to drugs of human lung adenocarcinoma cells Source: Eur Respir J 2006; 28: Suppl. 50, 325s Year: 2006 Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker? Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007 Targeted therapy in nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 284–298 Year: 2009